Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...

ResMed (NYSE:RMD) reported solid financial performance for the quarter ending March 31, 2025, with sales increasing to $1,292 million and net income reaching $365 million year-over-year. The company ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the third quarter of fiscal 2025 were $2.37, up 11.3% year over year.

Q3 2025 Management View CEO Mick Farrell highlighted strong financial performance, with revenue growth, gross margin expansion, and robust free cash flow generation. He attributed this to disciplined ...

Sleep software company ResMed, which is based in San Diego, ranked number nine on LinkedIn's list. ResMed makes medical devices for sleep disorders and employes around 3500 people in Australia.

A compound annual growth rate (CAGR) of 6.8% is anticipated for the market, which is expected to reach USD 3,829.7 million in 2025 and climb to USD 7,389.6 million by 2035.

The Breas Z2 Auto is a good option for travelers who value simplicity. The machine comes with a bunch of accessories right in the box, including a waterless humidifying attachment (called a ...

Learn More I've been keeping a close eye on the ResMed Inc (ASX: RMD) share price for a while now. There's a lot to like about ResMed. I'm particularly keen on the fact that the company has a ...

And here are three ASX shares that analysts rate as buys that tick that box for me. ResMed is the global leader in CPAP machines and masks used to treat sleep apnoea, a growing health issue worldwide.

ResMed RMD shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.